Failure to Satisfy Listing Rule (Form 8-K)

On December 8, 2025, Clearside Biomedical, Inc. (the "Company") filed a Form 25 (Notification of Removal of Listing) (the "Company Form 25") with the U.S. Securities and Exchange Commission (the "SEC") to complete the previously disclosed process to delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from The Nasdaq Stock Market LLC ("Nasdaq") and terminate registration of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in advance of Nasdaq's anticipated filing of a Form 25-NSEwith the SEC.

As previously disclosed, on November 24, 2025, the Company received written notice from the staff of Nasdaq notifying the Company that, as a result of the Company's filing of a voluntary petition (Case No. 25-12109)for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware, the staff of Nasdaq had determined that the Common Stock would be delisted from Nasdaq and Nasdaq would file a Form 25-NSEwith the SEC to remove the Common Stock from listing on Nasdaq and terminate the registration of the Common Stock under Section 12(b) of the Exchange Act. The Common Stock was suspended from trading on Nasdaq as of December 1, 2025, and the Common Stock began trading on the OTC Pink Limited Market on December 1, 2025. As of December 8, 2025, Nasdaq had not filed a Form 25-NSEwith the SEC. Accordingly, the Company filed the Company Form 25 to complete the process of delisting the Common Stock from Nasdaq when the Company Form 25 becomes effective no earlier than December 18, 2025. The Company Form 25 will also serve to deregister the Common Stock under Section 12(b) the Exchange Act, effective 90 days thereafter, which will reduce certain SEC reporting obligations of the Company.